See more : Linewell Software Co., Ltd. (603636.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Tabula Rasa HealthCare, Inc. (TRHC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tabula Rasa HealthCare, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- GTI Energy Ltd (GTRIF) Income Statement Analysis – Financial Results
- Munsin Garment Corporation (2916.TWO) Income Statement Analysis – Financial Results
- Intellipharmaceutics International Inc. (IPCI.TO) Income Statement Analysis – Financial Results
- Freedom Acquisition I Corp. (FACT-WT) Income Statement Analysis – Financial Results
- Maxis Berhad (6012.KL) Income Statement Analysis – Financial Results
Tabula Rasa HealthCare, Inc. (TRHC)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.tabularasahealthcare.com
About Tabula Rasa HealthCare, Inc.
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization; and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. Further, the company provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2021, it served approximately 150 healthcare organizations; and 350 health plans and approximately 18,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 299.52M | 331.26M | 297.22M | 284.71M | 204.27M | 134.55M | 94.06M | 70.04M | 48.43M | 25.14M |
| Cost of Revenue | 232.60M | 233.36M | 204.81M | 181.36M | 137.67M | 93.66M | 65.18M | 49.13M | 37.81M | 20.92M |
| Gross Profit | 66.91M | 97.90M | 92.41M | 103.35M | 66.60M | 40.89M | 28.89M | 20.91M | 10.62M | 4.22M |
| Gross Profit Ratio | 22.34% | 29.56% | 31.09% | 36.30% | 32.60% | 30.39% | 30.71% | 29.86% | 21.92% | 16.79% |
| Research & Development | 14.48M | 19.79M | 18.18M | 21.74M | 12.22M | 5.63M | 3.81M | 2.88M | 1.66M | 1.34M |
| General & Administrative | 74.97M | 73.76M | 65.38M | 50.90M | 28.18M | 21.18M | 11.83M | 7.12M | 3.97M | 2.48M |
| Selling & Marketing | 10.49M | 25.97M | 21.55M | 25.27M | 9.67M | 5.54M | 3.86M | 2.88M | 2.27M | 1.78M |
| SG&A | 85.47M | 99.73M | 86.93M | 76.17M | 37.85M | 26.72M | 15.69M | 10.00M | 6.24M | 4.26M |
| Other Expenses | 23.35M | 47.71M | 45.04M | 34.28M | 16.80M | 0.00 | 639.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 123.30M | 167.23M | 150.15M | 132.19M | 66.87M | 41.86M | 24.62M | 16.81M | 9.72M | 6.71M |
| Cost & Expenses | 355.90M | 400.58M | 354.96M | 313.54M | 204.54M | 135.52M | 89.79M | 65.93M | 47.53M | 27.63M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.03M | 9.11M | 20.74M | 15.99M | 906.00K | 688.00K | 4.49M | 5.92M | 1.35M | 833.00K |
| Depreciation & Amortization | 31.74M | 47.71M | 45.04M | 34.28M | 16.80M | 9.51M | 5.12M | 3.93M | 1.82M | 1.12M |
| EBITDA | -24.64M | -21.62M | -20.35M | 1.63M | 16.53M | 8.54M | 3.89M | 8.04M | 2.71M | -1.76M |
| EBITDA Ratio | -8.23% | -6.53% | -4.27% | 1.91% | 8.09% | 6.35% | 9.98% | 11.48% | 5.60% | -5.46% |
| Operating Income | -56.38M | -69.32M | -57.74M | -28.83M | -49.74M | 5.20M | 4.55M | 6.17M | 107.00K | -2.49M |
| Operating Income Ratio | -18.82% | -20.93% | -19.43% | -10.13% | -24.35% | 3.87% | 4.84% | 8.80% | 0.22% | -9.91% |
| Total Other Income/Expenses | -20.56M | -9.11M | -20.74M | -15.99M | -906.00K | -688.00K | -10.26M | -6.64M | -2.41M | -1.38M |
| Income Before Tax | -76.95M | -78.43M | -86.13M | -48.64M | -50.65M | 4.51M | -5.71M | -2.54M | -1.52M | -3.87M |
| Income Before Tax Ratio | -25.69% | -23.68% | -28.98% | -17.08% | -24.79% | 3.35% | -6.07% | -3.62% | -3.13% | -15.40% |
| Income Tax Expense | 389.00K | 627.00K | -5.17M | -16.20M | -3.38M | -9.78M | 541.00K | 328.00K | -409.00K | 833.00K |
| Net Income | -77.33M | -79.06M | -80.97M | -32.44M | -47.27M | 14.30M | -6.25M | -2.86M | -1.11M | -3.87M |
| Net Income Ratio | -25.82% | -23.86% | -27.24% | -11.39% | -23.14% | 10.63% | -6.64% | -4.09% | -2.29% | -15.40% |
| EPS | -3.18 | -3.39 | -3.71 | -1.57 | -2.48 | 0.76 | -0.83 | -0.29 | -0.11 | -0.39 |
| EPS Diluted | -3.18 | -3.39 | -3.71 | -1.57 | -2.48 | 0.68 | -0.54 | -0.29 | -0.11 | -0.39 |
| Weighted Avg Shares Out | 24.29M | 23.29M | 21.82M | 20.62M | 19.10M | 16.73M | 7.49M | 9.86M | 9.86M | 9.86M |
| Weighted Avg Shares Out (Dil) | 24.29M | 23.29M | 21.82M | 20.62M | 19.10M | 18.77M | 11.59M | 9.86M | 9.86M | 9.86M |
Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Lags Revenue Estimates
Tabula Rasa HealthCare Inks Deal with ASCP to offer MedWise® to Consultant Care Pharmacists
TRHC Continues to Experience PACE Growth
New Studies Prove Direct Link Between MedWise® and Better Health Outcomes Including Reduced Healthcare Costs
TRHC Hosts PACE Medical Directors at 2021 Clinical Advisory Panel Meeting
CareVention HealthCare Inks Shared Service Deal with PACE Association of Michigan
Tabula Rasa and Hesperos Receive $1.9M National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease
TRHC and Drake University Partner to Demonstrate Value of Pairing Remote Patient Monitoring and MedWise® to Enhance Health Care in Rural Areas via Telehealth
Tabula Rasa HealthCare Expands MedWise® Technology Offerings to Key Markets
Tabula Rasa Partners with eHealth to Enhance Community Pharmacy Access to Medicare Plan Reviews Through New Clinical Bundle
Source: https://incomestatements.info
Category: Stock Reports